Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment
Retrieved on:
Monday, April 1, 2024
Other Health, Seniors, Other Science, Pharmaceutical, Research, Mental Health, Medical Devices, Hospitals, Consumer, Science, Clinical Trials, Managed Care, Medical Supplies, Biotechnology, Neurology, Health, Health Technology, Health Insurance, Brain, Deficit spending, Cognitive deficit, CSF, Patient, Evaluation, PET, Biomarker, University, Population Health Management, Cerebrospinal fluid, Diagnosis, Pathology
The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
Key Points:
- The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
- The new research, “ Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment ,” used a budget impact model in a hypothetical 1 million-member health plan to assess the economic utility of the PrecivityAD blood test.
- Overall, the PrecivityAD blood test was associated with a cost savings of $643 per Alzheimer’s disease case (9% cost savings) identified.
- We believe the use of the PrecivityAD blood test in the clinical care pathway may prevent unnecessary testing, provide cost savings and reduce the burden on both patients and health plans.”